ArticleOncotarget2015
IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- CAR-T cell therapy: potential for paediatric brain tumours-an update.Journal of neuro-oncology · 2026Review
- The Fibrotic-Cancer Continuum in IPF: Shared Mechanisms, Clinical Implications and Therapeutic Challenges.Life (Basel, Switzerland) · 2026Review
- Fibroblast TGF-β signaling defines spatial tumor ecosystems linked to immune checkpoint blockade resistance.Communications biology · 2025Article
- Inflammatory cytokines and specific factors influencing lung cancer progression.Cancer pathogenesis and therapy · 2025Review
- IL-13/IL-13Rα2 axis promotes proliferation of angiosarcoma cells.Scientific reports · 2025Article
- Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.International journal of molecular sciences · 2024Review
- UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment.Nature communications · 2024Article
- Exploring the causal relationship between the immune cell-inflammatory factor axis and lung cancer: a Mendelian randomization study.Frontiers in oncology · 2024Article
- Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?Frontiers in oncology · 2024Review
- A comparative study of the arazyme-based fusion proteins with various ligands for more effective targeting cancer therapy: anResearch in pharmaceutical sciences · 2023Article
- Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide.Biomolecules · 2023Article
- Anoikis-related genes combined with single cell sequencing: Insights into model specification of lung adenocarcinoma and applicability for prognosis and therapy.Frontiers in cell and developmental biology · 2023Article
- Review
- Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.Frontiers in immunology · 2022Review
- Article
- Article
- Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.International journal of molecular sciences · 2019Review
- The Two Sides of YY1 in Cancer: A Friend and a Foe.Frontiers in oncology · 2019Review
- IRS-1 increases TAZ expression and promotes osteogenic differentiation in rat bone marrow mesenchymal stem cells.Biology open · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-13 receptor subunit alpha-2 (IL13Rα2) is associated with poor prognosis in some cancers. However, the role of IL13Rα2 in lung cancer remains unknown. We showed that IL13Rα2 overexpression was associated with late stages of disease progression and shorter disease-free survival (DFS) as well as overall survival (OS) in resected lung cancer patients. IL13Rα2 promoted the migration, invasion and anoikis resistance of lung cancer cells in vitro. Silencing of IL13Rα2 in lung cancer cells decreased invasion in vitro and lung metastasis in vivo. IL13Rα2 activated phosphatidylinositol 3 kinase (PI3K), Akt, and transcriptional coactivator with PDZ-binding motif (TAZ). Inhibition of PI3K attenuated activation of TAZ and its downstream target genes by IL13Rα2. We suggest that inhibition of IL13Rα2 is a potential therapeutic approach in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.